NCT04177004
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 14 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 22 words
- Primary endpoints: details revised at 1 of 4 entries
- Study completion pushed from Oct 27, 2026 to Mar 23, 2027
- Secondary endpoints: details revised at 15 of 15 entries
- Minor Primary completion moved earlier from Oct 27, 2026 to Dec 29, 2025v15
- Notable Trial status: Suspended to Active, Not Recruiting
- Enrollment target: estimated 53 to confirmed 52
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Accrual goal met
- Site details revised
- Notable Trial status: Active, Not Recruiting to Recruiting
- Primary and study completion dates: Oct 27, 2025 to Oct 27, 2026
- Enrollment target: 43 to 53
- Site details revised
Show 8 earlier versionsHide 8 earlier versions
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 36 to confirmed 43
- Site details revised
- Notable Primary and study completion dates: Dec 31, 2024 to Oct 27, 2025v10
- Notable Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v9
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Dec 31, 2022 to Dec 31, 2023
- Start date changed from estimate of May 15, 2021 to Apr 30, 2021
- Site details revised
- Notable Primary and study completion dates: Jul 29, 2021 to Dec 31, 2022
- Start date: Jan 15, 2021 to May 15, 2021
- Notable Start date: Jul 1, 2020 to Jan 15, 2021v4
- Notable Start date: Apr 1, 2020 to Jul 1, 2020v3
- Notable Start date: Jan 1, 2020 to Apr 1, 2020v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity. HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity. TRANSPLANT: Patients undergo stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.
CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity. TRANSPLANT: Patients undergo stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity.
Procedures: Allogeneic Hematopoietic Stem Cell Transplantation
Drugs: Cyclophosphamide, Etoposide, Goat Milk, Sirolimus, Tacrolimus
Radiation: Fractionated Stereotactic Radiation Therapy
Biologicals: Palifermin
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States